Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

US Patent 11559583 · Granted Jan 24, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

IL31-binding polypeptides and uses thereof2025
Method of making afucosylated anti-FGFR2IIIB antibodies2025
CD80 extracellular domain polypeptides and their use in cancer treatment2025
CD80 extracellular domain polypeptides and their use in cancer treatment2025
Method and system for battery management including bypassing battery cells in a 2025
Method and system for battery management including bypassing battery cells in a 2024
Compositions and methods for inhibition of the JAK pathway2023
B7-H4 antibodies and methods of use thereof2023
Methods of treatment with CD80 extracellular domain polypeptides2023
Anticancer agents2023
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected canc2023
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected canc2023